Ramucirumab is a monoclonal antibody developed from a human Fab antibody fragment targeting VEGFR-2 [24,25], and approved for the treatment of advanced gastric cancer, gastroesophageal junction adenocarcinoma cancer, non-small cell lung cancer, and metastatic colorectal cancer [2,3,26,27]. Here, KDR is linked to non-small cell lung carcinoma.